{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:30:09Z","timestamp":1790803809076,"version":"4.1.0"},"reference-count":114,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["seminarsinnuclearmedicine.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Nuclear Medicine"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1053\/j.semnuclmed.2014.10.006","type":"journal-article","created":{"date-parts":[[2015,2,20]],"date-time":"2015-02-20T03:02:06Z","timestamp":1424401326000},"page":"151-162","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":118,"title":["F-18 Fluoromisonidazole for Imaging Tumor Hypoxia: Imaging the Microenvironment for Personalized Cancer Therapy"],"prefix":"10.1053","volume":"45","author":[{"given":"Joseph G.","family":"Rajendran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth A.","family":"Krohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1053\/j.semnuclmed.2014.10.006_bib1","doi-asserted-by":"crossref","first-page":"737","DOI":"10.2214\/AJR.11.7483","article-title":"Personalized tumor response assessment in the era of molecular medicine: Cancer-specific and therapy-specific response criteria to complement pitfalls of RECIST","volume":"198","author":"Nishino","year":"2012","journal-title":"AJR Am J Roentgenol"},{"issue":"3","key":"10.1053\/j.semnuclmed.2014.10.006_bib2","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1097\/CCO.0b013e32835ff318","article-title":"Targeted therapies of solid cancers: New options, new challenges","volume":"25","author":"Awada","year":"2013","journal-title":"Curr Opin Oncol"},{"key":"10.1053\/j.semnuclmed.2014.10.006_bib3","first-page":"74","article-title":"Tumour anoxia and the response to radiation","author":"Thomlinson","year":"1965","journal-title":"Sci Basis Med Annu Rev"},{"issue":"5","key":"10.1053\/j.semnuclmed.2014.10.006_bib4","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: The next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"issue":"3","key":"10.1053\/j.semnuclmed.2014.10.006_bib5","first-page":"244","article-title":"Hypoxia and tumor metabolism in radiation oncology: Targets visualized by positron emission tomography","volume":"57","author":"Wijsman","year":"2013","journal-title":"Q J Nucl Med Mol Imaging"},{"issue":"2","key":"10.1053\/j.semnuclmed.2014.10.006_bib6","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S1536-1632(03)00045-3","article-title":"Anatomolecular imaging with 2-deoxy-2-[18F]fluoro-d-glucose: Bench to outpatient center","volume":"5","author":"Wahl","year":"2003","journal-title":"Mol Imaging Biol"},{"issue":"5645","key":"10.1053\/j.semnuclmed.2014.10.006_bib7","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1126\/science.1090585","article-title":"Molecular imaging: Looking at problems, seeing solutions","volume":"302","author":"Herschman","year":"2003","journal-title":"Science"},{"issue":"2","key":"10.1053\/j.semnuclmed.2014.10.006_bib8","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/S0360-3016(00)01469-3","article-title":"Predictive assays: Will they ever have a role in the clinic?","volume":"49","author":"Peters","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1053\/j.semnuclmed.2014.10.006_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/RLU.0b013e3182708777","article-title":"Detection of hypoxia with 18F-fluoromisonidazole (18F-FMISO) PET\/CT in suspected or proven pancreatic cancer","volume":"38","author":"Segard","year":"2013","journal-title":"Clin Nucl Med"},{"issue":"10","key":"10.1053\/j.semnuclmed.2014.10.006_bib10","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1089\/ars.2013.5378","article-title":"The clinical importance of assessing tumor hypoxia: Relationship of tumor hypoxia to prognosis and therapeutic opportunities","volume":"21","author":"Walsh","year":"2014","journal-title":"Antioxid Redox Signal"},{"issue":"1","key":"10.1053\/j.semnuclmed.2014.10.006_bib11","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/bies.201100049","article-title":"Cancer: A de-repression of a default survival program common to all cells?: A life-history perspective on the nature of cancer","volume":"34","author":"Vincent","year":"2012","journal-title":"Bioessays"},{"issue":"3 Pt 1","key":"10.1053\/j.semnuclmed.2014.10.006_bib12","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1097\/00005537-200003000-00008","article-title":"Identification of genes overexpressed in head and neck squamous cell carcinoma using a combination of complementary DNA subtraction and microarray analysis","volume":"110","author":"Villaret","year":"2000","journal-title":"Laryngoscope"},{"issue":"2 suppl 8","key":"10.1053\/j.semnuclmed.2014.10.006_bib13","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S0093-7754(01)90211-8","article-title":"Biological consequences of tumor hypoxia","volume":"28","author":"Hockel","year":"2001","journal-title":"Semin Oncol"},{"issue":"13 spec no","key":"10.1053\/j.semnuclmed.2014.10.006_bib14","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1016\/S0959-8049(00)00159-3","article-title":"Hypoxia modulated gene expression: Angiogenesis, metastasis and therapeutic exploitation","volume":"36","author":"Dachs","year":"2000","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1053\/j.semnuclmed.2014.10.006_bib15","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1038\/sj.leu.2403332","article-title":"Activation of the HIF pathway in childhood ALL, prognostic implications of VEGF","volume":"18","author":"Wellmann","year":"2004","journal-title":"Leukemia"},{"issue":"2","key":"10.1053\/j.semnuclmed.2014.10.006_bib16","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S0360-3016(00)00677-5","article-title":"Cancer vascularization: Implications in radiotherapy?","volume":"48","author":"Kourkourakis","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1053\/j.semnuclmed.2014.10.006_bib17","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2741\/3616","article-title":"The role of hypoxia and acidosis in promoting metastasis and resistance to chemotherapy","volume":"15","author":"DeClerck","year":"2010","journal-title":"Front Biosci"},{"issue":"24","key":"10.1053\/j.semnuclmed.2014.10.006_bib18","doi-asserted-by":"crossref","first-page":"5928","DOI":"10.1158\/1078-0432.CCR-10-1360","article-title":"Hypoxia and hypoxia-inducible factors: Master regulators of metastasis","volume":"16","author":"Lu","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"5516","key":"10.1053\/j.semnuclmed.2014.10.006_bib19","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1126\/science.1059817","article-title":"HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: Implications for O2 sensing","volume":"292","author":"Ivan","year":"2001","journal-title":"Science"},{"issue":"1","key":"10.1053\/j.semnuclmed.2014.10.006_bib20","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0959-437X(00)00152-0","article-title":"The von Hippel-Lindau tumor suppressor protein","volume":"11","author":"Ivan","year":"2001","journal-title":"Curr Opin Genet Dev"},{"issue":"50","key":"10.1053\/j.semnuclmed.2014.10.006_bib21","doi-asserted-by":"crossref","first-page":"32253","DOI":"10.1074\/jbc.271.50.32253","article-title":"Activation of hypoxia-inducible transcription factor depends primarily upon redox-sensitive stabilization of its alpha subunit","volume":"271","author":"Huang","year":"1996","journal-title":"J Biol Chem"},{"issue":"11","key":"10.1053\/j.semnuclmed.2014.10.006_bib22","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1038\/emboj.2012.125","article-title":"The updated biology of hypoxia-inducible factor","volume":"31","author":"Greer","year":"2012","journal-title":"EMBO J"},{"issue":"4","key":"10.1053\/j.semnuclmed.2014.10.006_bib23","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1254\/jphs.10R20FM","article-title":"Pathophysiological response to hypoxia\u2014From the molecular mechanisms of malady to drug discovery: Hypoxia-inducible factor-1 (HIF-1)-active cells as a target for cancer therapy","volume":"115","author":"Kizaka-Kondoh","year":"2011","journal-title":"J Pharmacol Sci"},{"key":"10.1053\/j.semnuclmed.2014.10.006_bib24","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/978-3-540-78281-0_3","article-title":"HIF-1alpha and cancer therapy","volume":"180","author":"Koh","year":"2010","journal-title":"Recent Results Cancer Res"},{"key":"10.1053\/j.semnuclmed.2014.10.006_bib25","series-title":"Radiobiology for the Radiologist","author":"Hall","year":"2000"},{"issue":"1","key":"10.1053\/j.semnuclmed.2014.10.006_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0304-3835(03)00012-0","article-title":"Prognostic significance of tumor oxygenation in humans","volume":"195","author":"Evans","year":"2003","journal-title":"Cancer Lett"},{"issue":"4","key":"10.1053\/j.semnuclmed.2014.10.006_bib27","first-page":"883","article-title":"Candidate genes for the hypoxic tumor phenotype","volume":"60","author":"Koong","year":"2000","journal-title":"Cancer Res"},{"issue":"18","key":"10.1053\/j.semnuclmed.2014.10.006_bib28","first-page":"4525","article-title":"Hypoxic cervical cancers with low apoptotic index are highly aggressive","volume":"59","author":"Hockel","year":"1999","journal-title":"Cancer Res"},{"issue":"7","key":"10.1053\/j.semnuclmed.2014.10.006_bib29","doi-asserted-by":"crossref","first-page":"790","DOI":"10.2174\/187152008785914798","article-title":"Tumour hypoxia affects the responsiveness of cancer cells to chemotherapy and promotes cancer progression","volume":"8","author":"Cosse","year":"2008","journal-title":"Anticancer Agents Med Chem"},{"issue":"5","key":"10.1053\/j.semnuclmed.2014.10.006_bib30","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.3109\/10428194.2012.733874","article-title":"Hypoxia inducible factor-1alpha induces chemoresistance phenotype in non\u2013Hodgkin lymphoma cell line via up-regulation of Bcl-xL","volume":"54","author":"Hernandez-Luna","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"10.1053\/j.semnuclmed.2014.10.006_bib31","doi-asserted-by":"crossref","first-page":"e98882","DOI":"10.1371\/journal.pone.0098882","article-title":"HIF-1alpha inhibition reverses multidrug resistance in colon cancer cells via downregulation of MDR1\/P-glycoprotein","volume":"9","author":"Chen","year":"2014","journal-title":"PLoS One"},{"issue":"4","key":"10.1053\/j.semnuclmed.2014.10.006_bib32","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S1357-4310(00)01677-4","article-title":"Exploiting the hypoxic cancer cell: Mechanisms and therapeutic strategies","volume":"6","author":"Brown","year":"2000","journal-title":"Mol Med Today"},{"key":"10.1053\/j.semnuclmed.2014.10.006_bib33","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1186\/1471-2407-12-496","article-title":"PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumours","volume":"12","author":"McKeage","year":"2012","journal-title":"BMC Cancer"},{"key":"10.1053\/j.semnuclmed.2014.10.006_bib34","doi-asserted-by":"crossref","first-page":"3483","DOI":"10.2741\/2329","article-title":"Targeting tumors with hypoxia-activated cytotoxins","volume":"12","author":"Ahn","year":"2007","journal-title":"Front Biosci"},{"issue":"415","key":"10.1053\/j.semnuclmed.2014.10.006_bib35","first-page":"127P","article-title":"Imaging with F-18 FMISO-PET permits hypoxia directed radiotherapy dose escalation for head and neck cancer","volume":"44","author":"Rajendran","year":"2003","journal-title":"J Nucl Med"},{"issue":"4","key":"10.1053\/j.semnuclmed.2014.10.006_bib36","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/S0360-3016(00)01433-4","article-title":"A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy","volume":"49","author":"Chao","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1053\/j.semnuclmed.2014.10.006_bib37","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.ijrobp.2007.06.039","article-title":"Fluorine-18-labeled fluoromisonidazole positron emission and computed tomography-guided intensity-modulated radiotherapy for head and neck cancer: A feasibility study","volume":"70","author":"Lee","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"8","key":"10.1053\/j.semnuclmed.2014.10.006_bib38","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.3109\/0284186X.2012.759273","article-title":"Hypoxia-targeted radiotherapy dose painting for head and neck cancer using (18)F-FMISO PET: A biological modeling study","volume":"52","author":"Chang","year":"2013","journal-title":"Acta Oncol"},{"issue":"1","key":"10.1053\/j.semnuclmed.2014.10.006_bib39","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.ijrobp.2006.11.061","article-title":"Hypoxia dose painting by numbers: A planning study","volume":"68","author":"Thorwarth","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"10.1053\/j.semnuclmed.2014.10.006_bib40","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.radonc.2011.07.029","article-title":"Hypoxia imaging with [F-18] FMISO-PET in head and neck cancer: Potential for guiding intensity modulated radiation therapy in overcoming hypoxia-induced treatment resistance","volume":"101","author":"Hendrickson","year":"2011","journal-title":"Radiother Oncol"},{"issue":"2","key":"10.1053\/j.semnuclmed.2014.10.006_bib41","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1200\/JCO.2001.19.2.535","article-title":"Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer","volume":"19","author":"Rischin","year":"2001","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1053\/j.semnuclmed.2014.10.006_bib42","doi-asserted-by":"crossref","first-page":"80","DOI":"10.5732\/cjc.012.10285","article-title":"Bioreductive prodrugs as cancer therapeutics: Targeting tumor hypoxia","volume":"33","author":"Guise","year":"2014","journal-title":"Chin J Cancer"},{"issue":"5","key":"10.1053\/j.semnuclmed.2014.10.006_bib43","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/nbt0512-381","article-title":"Hypoxia-activated prodrugs forge ahead in cancer","volume":"30","author":"Kling","year":"2012","journal-title":"Nat Biotechnol"},{"issue":"1","key":"10.1053\/j.semnuclmed.2014.10.006_bib44","first-page":"BR11","article-title":"Effect of carbogen on tumour oxygenation and 32P-colloid interstitial irradiation response","volume":"16","author":"Zhan","year":"2010","journal-title":"Med Sci Monit"},{"issue":"5","key":"10.1053\/j.semnuclmed.2014.10.006_bib45","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1158\/1078-0432.CCR-13-1730","article-title":"Improved recurrence-free survival with ARCON for anemic patients with laryngeal cancer","volume":"20","author":"Janssens","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1053\/j.semnuclmed.2014.10.006_bib46","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/j.mri.2012.02.015","article-title":"Imaging biomarkers to monitor response to the hypoxia-activated prodrug TH-302 in the MiaPaCa2 flank xenograft model","volume":"30","author":"Cardenas-Rodriguez","year":"2012","journal-title":"Magn Reson Imaging"},{"issue":"6","key":"10.1053\/j.semnuclmed.2014.10.006_bib47","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1007\/s00280-012-1852-8","article-title":"TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: Optimization of dosing regimens and schedules","volume":"69","author":"Liu","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1053\/j.semnuclmed.2014.10.006_bib48","doi-asserted-by":"crossref","DOI":"10.1007\/s00259-014-2810-y","article-title":"Advantage of FMISO-PET over FDG-PET for predicting histological response to preoperative chemotherapy in patients with oral squamous cell carcinoma","author":"Sato","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"10.1053\/j.semnuclmed.2014.10.006_bib49","doi-asserted-by":"crossref","first-page":"670","DOI":"10.2174\/15680096113139990004","article-title":"Targeting hypoxia for sensitization of tumors to radio- and chemotherapy","volume":"13","author":"Ghattass","year":"2013","journal-title":"Curr Cancer Drug Targets"},{"issue":"3","key":"10.1053\/j.semnuclmed.2014.10.006_bib50","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.radonc.2007.05.014","article-title":"Hypoxia-imaging with (18)F-Misonidazole and PET: Changes of kinetics during radiotherapy of head-and-neck cancer","volume":"83","author":"Eschmann","year":"2007","journal-title":"Radiother Oncol"},{"issue":"6","key":"10.1053\/j.semnuclmed.2014.10.006_bib51","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1093\/jrr\/rrt033","article-title":"A prospective clinical trial of tumor hypoxia imaging with 18F-fluoromisonidazole positron emission tomography and computed tomography (F-MISO PET\/CT) before and during radiation therapy","volume":"54","author":"Tachibana","year":"2013","journal-title":"J Radiat Res"},{"issue":"2","key":"10.1053\/j.semnuclmed.2014.10.006_bib52","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1093\/jjco\/hyr181","article-title":"Reoxygenation of glioblastoma multiforme treated with fractionated radiotherapy concomitant with temozolomide: Changes defined by 18F-fluoromisonidazole positron emission tomography: Two case reports","volume":"42","author":"Narita","year":"2012","journal-title":"Jpn J Clin Oncol"},{"issue":"13","key":"10.1053\/j.semnuclmed.2014.10.006_bib53","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1200\/JCO.2005.05.2878","volume":"24","author":"Rischin","year":"2006","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1053\/j.semnuclmed.2014.10.006_bib54","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1002\/ijc.28595","article-title":"Activity of the hypoxia-activated pro-drug TH-302 in hypoxic and perivascular regions of solid tumors and its potential to enhance therapeutic effects of chemotherapy","volume":"134","author":"Saggar","year":"2014","journal-title":"Int J Cancer"},{"issue":"8","key":"10.1053\/j.semnuclmed.2014.10.006_bib55","doi-asserted-by":"crossref","first-page":"636","DOI":"10.3109\/09553002.2014.916841","article-title":"Hypoxia as a biomarker for radioresistant cancer stem cells","volume":"90","author":"Peitzsch","year":"2014","journal-title":"Int J Radiat Biol"},{"issue":"9","key":"10.1053\/j.semnuclmed.2014.10.006_bib56","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s12149-011-0508-9","article-title":"18F-fluoromisonidazole positron emission tomography before treatment is a predictor of radiotherapy outcome and survival prognosis in patients with head and neck squamous cell carcinoma","volume":"25","author":"Kikuchi","year":"2011","journal-title":"Ann Nucl Med"},{"issue":"3","key":"10.1053\/j.semnuclmed.2014.10.006_bib57","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/CCO.0b013e3282faa0cb","article-title":"Role of positron emission tomography in the management of head and neck cancer in the molecular therapy era","volume":"20","author":"Garcia","year":"2008","journal-title":"Curr Opin Oncol"},{"issue":"18","key":"10.1053\/j.semnuclmed.2014.10.006_bib58","doi-asserted-by":"crossref","first-page":"5435","DOI":"10.1158\/1078-0432.CCR-05-1773","article-title":"Tumor hypoxia imaging with [F-18] fluoromisonidazole positron emission tomography in head and neck cancer","volume":"12","author":"Rajendran","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1053\/j.semnuclmed.2014.10.006_bib59","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1093\/jnci\/93.4.266","article-title":"Tumor hypoxia: Definitions and current clinical, biologic, and molecular aspects","volume":"93","author":"Hockel","year":"2001","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"10.1053\/j.semnuclmed.2014.10.006_bib60","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.radonc.2012.08.019","article-title":"Exploratory prospective trial of hypoxia-specific PET imaging during radiochemotherapy in patients with locally advanced head-and-neck cancer","volume":"105","author":"Zips","year":"2012","journal-title":"Radiother Oncol"},{"issue":"23","key":"10.1053\/j.semnuclmed.2014.10.006_bib61","first-page":"5721","article-title":"Detection of hypoxic cells by monoclonal antibody recognizing 2-nitroimidazole adducts","volume":"53","author":"Lord","year":"1993","journal-title":"Cancer Res"},{"issue":"2","key":"10.1053\/j.semnuclmed.2014.10.006_bib62","doi-asserted-by":"crossref","first-page":"222","DOI":"10.3109\/0284186X.2011.599815","article-title":"Dose prescription and treatment planning based on FMISO-PET hypoxia","volume":"51","author":"Toma-Dasu","year":"2012","journal-title":"Acta Oncol"},{"issue":"3","key":"10.1053\/j.semnuclmed.2014.10.006_bib63","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.ijrobp.2011.12.047","article-title":"Positron emission tomography\/computed tomography imaging of residual skull base chordoma before radiotherapy using fluoromisonidazole and fluorodeoxyglucose: Potential consequences for dose painting","volume":"84","author":"Mammar","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"11-12","key":"10.1053\/j.semnuclmed.2014.10.006_bib64","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/0360-3016(77)90140-7","article-title":"The proportion of hypoxic cells in a human tumor","volume":"2","author":"Denekamp","year":"1977","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1053\/j.semnuclmed.2014.10.006_bib65","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/0360-3016(80)90215-1","article-title":"On the nature of the radiobiologically hypoxic fraction in tumors","volume":"6","author":"Sutherland","year":"1980","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"7952","key":"10.1053\/j.semnuclmed.2014.10.006_bib66","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S0140-6736(76)91285-X","article-title":"Hypoxic cell sensitisers in radiotherapy","volume":"1","author":"Adams","year":"1976","journal-title":"Lancet"},{"issue":"26","key":"10.1053\/j.semnuclmed.2014.10.006_bib67","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJM197912273012606","article-title":"Hypoxic sensitizers\u2014Implications for radiation therapy","volume":"301","author":"Chapman","year":"1979","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1053\/j.semnuclmed.2014.10.006_bib68","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.clon.2007.03.010","article-title":"Chemical radiosensitizers for use in radiotherapy","volume":"19","author":"Wardman","year":"2007","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"1","key":"10.1053\/j.semnuclmed.2014.10.006_bib69","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1042\/bj2530287","article-title":"The potential diagram for oxygen at pH 7","volume":"253","author":"Wood","year":"1988","journal-title":"Biochem J"},{"key":"10.1053\/j.semnuclmed.2014.10.006_bib70","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S1054-3589(08)60023-X","article-title":"Development of radiosensitizers: A medicinal chemistry perspective","volume":"19","author":"Narayanan","year":"1982","journal-title":"Adv Pharmacol Chemother"},{"issue":"3-4","key":"10.1053\/j.semnuclmed.2014.10.006_bib71","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/0360-3016(82)90655-1","article-title":"In vitro and in vivo radiosensitization by 2-nitroimidazoles more electron-affinic than misonidazole","volume":"8","author":"Brown","year":"1982","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1053\/j.semnuclmed.2014.10.006_bib72","first-page":"H59","article-title":"Measurement of local cerebral blood flow with iodo [14C] antipyrine","volume":"234","author":"Sakurada","year":"1978","journal-title":"Am J Physiol"},{"issue":"2","key":"10.1053\/j.semnuclmed.2014.10.006_bib73","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/S0022-3565(25)13060-7","article-title":"Comparison of in vitro and in vivo models of drug transcytosis through the blood-brain barrier","volume":"253","author":"Pardridge","year":"1990","journal-title":"J Pharmacol Exp Ther"},{"issue":"suppl 2","key":"10.1053\/j.semnuclmed.2014.10.006_bib74","doi-asserted-by":"crossref","first-page":"129S","DOI":"10.2967\/jnumed.107.045914","article-title":"Molecular imaging of hypoxia","volume":"49","author":"Krohn","year":"2008","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1053\/j.semnuclmed.2014.10.006_bib75","first-page":"106","article-title":"Hypoxia-specific tumor imaging with 18F-fluoroazomycin arabinoside","volume":"46","author":"Piert","year":"2005","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1053\/j.semnuclmed.2014.10.006_bib76","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2307\/3575246","article-title":"Partition coefficient as a guide to the development of radiosensitizers which are less toxic than misonidazole","volume":"82","author":"Brown","year":"1980","journal-title":"Radiat Res"},{"key":"10.1053\/j.semnuclmed.2014.10.006_bib77","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/(SICI)1099-1344(199901)42:1<3::AID-JLCR160>3.0.CO;2-H","article-title":"Synthesis, 2H and 3H-labelling and preliminary biological evaluaation of a novel 2-nitroimidazole marker of tissue hypoxia","volume":"42","author":"Kumar","year":"1999","journal-title":"J Label Compounds Radiopharm"},{"issue":"3","key":"10.1053\/j.semnuclmed.2014.10.006_bib78","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S0969-8051(02)00442-0","article-title":"[18F]Fluoroazomycinarabinofuranoside (18FAZA) and [18F]Fluoromisonidazole (18FMISO): A comparative study of their selective uptake in hypoxic cells and PET imaging in experimental rat tumors","volume":"30","author":"Sorger","year":"2003","journal-title":"Nucl Med Biol"},{"key":"10.1053\/j.semnuclmed.2014.10.006_bib79","unstructured":"Bacchu V, Kumar P, Wiebe L: personal communication. In: Krohn K., editor, 2014"},{"issue":"11","key":"10.1053\/j.semnuclmed.2014.10.006_bib80","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1111\/j.1349-7006.1989.tb02267.x","article-title":"A new, potent 2-nitroimidazole nucleoside hypoxic cell radiosensitizer, RP170","volume":"80","author":"Sasai","year":"1989","journal-title":"Jpn J Cancer Res"},{"issue":"35","key":"10.1053\/j.semnuclmed.2014.10.006_bib81","doi-asserted-by":"crossref","first-page":"14620","DOI":"10.1073\/pnas.1102526108","article-title":"Preclinical evaluation and validation of [18F]HX4, a promising hypoxia marker for PET imaging","volume":"108","author":"Dubois","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1053\/j.semnuclmed.2014.10.006_bib82","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.radonc.2013.08.031","article-title":"Hypoxia imaging with [18F]HX4 PET in NSCLC patients: Defining optimal imaging parameters","volume":"109","author":"Zegers","year":"2013","journal-title":"Radiother Oncol"},{"issue":"2","key":"10.1053\/j.semnuclmed.2014.10.006_bib83","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s00259-008-0907-x","article-title":"[18F]EF3 is not superior to [18F]FMISO for PET-based hypoxia evaluation as measured in a rat rhabdomyosarcoma tumour model","volume":"36","author":"Dubois","year":"2009","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"10.1053\/j.semnuclmed.2014.10.006_bib84","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.radonc.2008.06.008","article-title":"Comparative pharmacokinetics, biodistribution, metabolism and hypoxia-dependent uptake of [18F]-EF3 and [18F]-MISO in rodent tumor models","volume":"89","author":"Mahy","year":"2008","journal-title":"Radiother Oncol"},{"issue":"8","key":"10.1053\/j.semnuclmed.2014.10.006_bib85","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.2967\/jnumed.112.116293","article-title":"18F-EF5 PET imaging as an early response biomarker for the hypoxia-activated prodrug SN30000 combined with radiation treatment in a non\u2013small cell lung cancer xenograft model","volume":"54","author":"Chitneni","year":"2013","journal-title":"J Nucl Med"},{"issue":"28","key":"10.1053\/j.semnuclmed.2014.10.006_bib86","doi-asserted-by":"crossref","first-page":"2932","DOI":"10.2174\/138161208786404380","article-title":"Imaging of tumor hypoxia to predict treatment sensitivity","volume":"14","author":"Minn","year":"2008","journal-title":"Curr Pharm Des"},{"issue":"9","key":"10.1053\/j.semnuclmed.2014.10.006_bib87","first-page":"1625","article-title":"Fluorodeoxyglucose uptake in human cancer cell lines is increased by hypoxia","volume":"36","author":"Clavo","year":"1995","journal-title":"J Nucl Med"},{"issue":"12","key":"10.1053\/j.semnuclmed.2014.10.006_bib88","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1007\/s00259-006-0175-6","article-title":"FDG\u2014A marker of tumour hypoxia? A comparison with [18F]fluoromisonidazole and pO2-polarography in metastatic head and neck cancer","volume":"33","author":"Zimny","year":"2006","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"7","key":"10.1053\/j.semnuclmed.2014.10.006_bib89","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1158\/1078-0432.CCR-0688-3","article-title":"Hypoxia and glucose metabolism in malignant tumors: Evaluation by [18F]fluoromisonidazole and [18F]fluorodeoxyglucose positron emission tomography imaging","volume":"10","author":"Rajendran","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1053\/j.semnuclmed.2014.10.006_bib90","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.radonc.2006.07.033","article-title":"Combined uptake of [18F]FDG and [18F]FMISO correlates with radiation therapy outcome in head-and-neck cancer patients","volume":"80","author":"Thorwarth","year":"2006","journal-title":"Radiother Oncol"},{"issue":"1","key":"10.1053\/j.semnuclmed.2014.10.006_bib91","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.radonc.2010.10.011","volume":"98","author":"Vera","year":"2011","journal-title":"Radiother Oncol"},{"issue":"10","key":"10.1053\/j.semnuclmed.2014.10.006_bib92","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1007\/BF01367595","article-title":"Fluorine-18 fluoromisonidazole tumour to muscle retention ratio for the detection of hypoxia in nasopharyngeal carcinoma","volume":"23","author":"Yeh","year":"1996","journal-title":"Eur J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2014.10.006_bib93","article-title":"Quantitative [F-18]fluoromisonidazole (FMISO) imaging of hypoxia using image-based blood surrogates","author":"Muzi","year":"2012","journal-title":"J Nucl Med"},{"issue":"2","key":"10.1053\/j.semnuclmed.2014.10.006_bib94","first-page":"139","article-title":"A new role of PET\/CT for target delineation for radiotherapy treatment planning for head and neck carcinomas","volume":"15","author":"Zygogianni","year":"2012","journal-title":"Hell J Nucl Med"},{"issue":"2","key":"10.1053\/j.semnuclmed.2014.10.006_bib95","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S0360-3016(96)00325-2","article-title":"Quantifying regional hypoxia in human tumors with positron emission tomography of [18F]fluoromisonidazole: A pretherapy study of 37 patients","volume":"36","author":"Rasey","year":"1996","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"8","key":"10.1053\/j.semnuclmed.2014.10.006_bib96","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.2967\/jnumed.112.115014","article-title":"PET imaging of tumor hypoxia using 18F-fluoroazomycin arabinoside in stage III-IV non\u2013small cell lung cancer patients","volume":"54","author":"Bollineni","year":"2013","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1053\/j.semnuclmed.2014.10.006_bib97","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/imammb\/dqr002","article-title":"Applying a patient-specific bio-mathematical model of glioma growth to develop virtual [18F]-FMISO-PET images","volume":"29","author":"Gu","year":"2012","journal-title":"Math Med Biol"},{"issue":"1","key":"10.1053\/j.semnuclmed.2014.10.006_bib98","doi-asserted-by":"crossref","first-page":"36","DOI":"10.2967\/jnumed.108.055467","article-title":"Complementary but distinct roles for MRI and 18F-fluoromisonidazole PET in the assessment of human glioblastomas","volume":"50","author":"Swanson","year":"2009","journal-title":"J Nucl Med"},{"issue":"2","key":"10.1053\/j.semnuclmed.2014.10.006_bib99","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.semradonc.2010.10.001","article-title":"Molecular imaging-based dose painting: A novel paradigm for radiation therapy prescription","volume":"21","author":"Bentzen","year":"2011","journal-title":"Semin Radiat Oncol"},{"issue":"2","key":"10.1053\/j.semnuclmed.2014.10.006_bib100","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2967\/jnumed.112.109330","article-title":"High reproducibility of tumor hypoxia evaluated by 18F-fluoromisonidazole PET for head and neck cancer","volume":"54","author":"Okamoto","year":"2013","journal-title":"J Nucl Med"},{"issue":"2","key":"10.1053\/j.semnuclmed.2014.10.006_bib101","first-page":"253","article-title":"Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non\u2013small cell lung cancer and head and neck cancer before radiotherapy","volume":"46","author":"Eschmann","year":"2005","journal-title":"J Nucl Med"},{"issue":"11","key":"10.1053\/j.semnuclmed.2014.10.006_bib102","doi-asserted-by":"crossref","first-page":"773","DOI":"10.2176\/nmc.ra2013-0256","article-title":"Usefulness of FMISO-PET for glioma analysis","volume":"53","author":"Kobayashi","year":"2013","journal-title":"Neurol Med Chir (Tokyo)"},{"issue":"2","key":"10.1053\/j.semnuclmed.2014.10.006_bib103","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/0360-3016(95)00170-4","article-title":"Evaluation of oxygenation status during fractionated radiotherapy in human nonsmall cell lung cancers using [F-18]fluoromisonidazole positron emission tomography","volume":"33","author":"Koh","year":"1995","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1053\/j.semnuclmed.2014.10.006_bib104","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/1748-717X-7-157","article-title":"Multimodal hypoxia imaging and intensity modulated radiation therapy for unresectable non\u2013small-cell lung cancer: The HIL trial","volume":"7","author":"Askoxylakis","year":"2012","journal-title":"Radiat Oncol"},{"issue":"3","key":"10.1053\/j.semnuclmed.2014.10.006_bib105","doi-asserted-by":"crossref","first-page":"333","DOI":"10.2967\/jnumed.112.111963","article-title":"18F-fluoromisonidazole PET\/CT: A potential tool for predicting primary endocrine therapy resistance in breast cancer","volume":"54","author":"Cheng","year":"2013","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2014.10.006_bib106","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1186\/1479-5876-11-185","article-title":"Prognostic assessment of hypoxia and metabolic markers in cervical cancer using automated digital image analysis of immunohistochemistry","volume":"11","author":"Kim","year":"2013","journal-title":"J Transl Med"},{"issue":"4","key":"10.1053\/j.semnuclmed.2014.10.006_bib107","doi-asserted-by":"crossref","first-page":"541","DOI":"10.2967\/jnumed.110.083717","article-title":"Multiagent PET for risk characterization in sarcoma","volume":"52","author":"Eary","year":"2011","journal-title":"J Nucl Med"},{"issue":"6","key":"10.1053\/j.semnuclmed.2014.10.006_bib108","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/nrc3064","article-title":"Targeting hypoxia in cancer therapy","volume":"11","author":"Wilson","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"10.1053\/j.semnuclmed.2014.10.006_bib109","first-page":"v","article-title":"Tumor microenvironment and cellular stress: Signaling, metabolism, imaging, and therapeutic targets. Preface","volume":"772","author":"Koumenis","year":"2014","journal-title":"Adv Exp Med Biol"},{"issue":"2","key":"10.1053\/j.semnuclmed.2014.10.006_bib110","doi-asserted-by":"crossref","first-page":"292","DOI":"10.2307\/3576986","article-title":"Characterization of radiolabeled fluoromisonidazole as a probe for hypoxic cells","volume":"111","author":"Rasey","year":"1987","journal-title":"Radiat Res"},{"issue":"1","key":"10.1053\/j.semnuclmed.2014.10.006_bib111","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2307\/3574491","article-title":"Electron-affinic sensitization. VII. A correlation between structures, one-electron reduction potentials, and efficiencies of nitroimidazoles as hypoxic cell radiosensitizers","volume":"67","author":"Adams","year":"1976","journal-title":"Radiat Res"},{"issue":"3","key":"10.1053\/j.semnuclmed.2014.10.006_bib112","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1148\/radiology.194.3.7862981","article-title":"Development of F-18-labeled fluoroerythronitroimidazole as a PET agent for imaging tumor hypoxia","volume":"194","author":"Yang","year":"1995","journal-title":"Radiology"},{"issue":"11","key":"10.1053\/j.semnuclmed.2014.10.006_bib113","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1038\/sj.bjc.6601862","article-title":"In vivo evaluation of [18F]fluoroetanidazole as a new marker for imaging tumour hypoxia with positron emission tomography","volume":"90","author":"Barthel","year":"2004","journal-title":"Br J Cancer"},{"issue":"3","key":"10.1053\/j.semnuclmed.2014.10.006_bib114","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s002800100324","article-title":"Pharmacokinetics of EF5 [2-(2-nitro-1-H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl) acetamide] in human patients: Implications for hypoxia measurements in vivo by 2-nitroimidazoles","volume":"48","author":"Koch","year":"2001","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["Seminars in Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000129981400124X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000129981400124X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T19:55:15Z","timestamp":1747684515000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000129981400124X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3]]},"references-count":114,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["S000129981400124X"],"URL":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2014.10.006","relation":{},"ISSN":["0001-2998"],"issn-type":[{"value":"0001-2998","type":"print"}],"subject":[],"published":{"date-parts":[[2015,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"F-18 Fluoromisonidazole for Imaging Tumor Hypoxia: Imaging the Microenvironment for Personalized Cancer Therapy","name":"articletitle","label":"Article Title"},{"value":"Seminars in Nuclear Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2014.10.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}